Mineralys Therapeutics, Common Stock Price on May 21, 2024
| MLYS Stock | 13.14 0.19 1.43% |
If you're considering investing in Mineralys Stock, it is important to understand the factors that can impact its price. As of today, the current price of Mineralys Therapeutics, stands at 13.14, as last reported on the 11th of December 2024, with the highest price reaching 13.34 and the lowest price hitting 12.59 during the day. Mineralys Therapeutics, appears to be not too volatile, given 3 months investment horizon. Mineralys Therapeutics, has Sharpe Ratio of 0.0697, which conveys that the firm had a 0.0697% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Mineralys Therapeutics,, which you can use to evaluate the volatility of the firm. Please exercise Mineralys Therapeutics,'s Downside Deviation of 3.53, risk adjusted performance of 0.0511, and Mean Deviation of 2.77 to check out if our risk estimates are consistent with your expectations.
At this time, Mineralys Therapeutics,'s Total Stockholder Equity is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 264.2 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 31 M in 2024. . At this time, Mineralys Therapeutics,'s Price Book Value Ratio is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 1.36 in 2024, whereas Price Earnings To Growth Ratio is likely to drop (0.03) in 2024. Mineralys Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Mineralys |
Sharpe Ratio = 0.0697
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MLYS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.95 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Mineralys Therapeutics, is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mineralys Therapeutics, by adding it to a well-diversified portfolio.
Price Book 2.7748 | Book Value 4.762 | Enterprise Value 660.5 M | Enterprise Value Ebitda (7.41) | Shares Float 23.9 M |
Related Headline
Valneva SE Headline on 21st of May 2024
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Sc... by benzinga.com
Saint-Herblain , May 21, 2024 Valneva SE , a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer and Executive
Mineralys Therapeutics, Valuation on May 21, 2024
It is possible to determine the worth of Mineralys Therapeutics, on a given historical date. On May 21, 2024 Mineralys was worth 12.78 at the beginning of the trading date compared to the closed value of 12.91. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Mineralys Therapeutics, stock. Still, in general, we apply an absolute valuation method to find Mineralys Therapeutics,'s value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mineralys Therapeutics, where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Mineralys Therapeutics,'s related companies.
| Open | High | Low | Close | Volume | |
| 12.96 | 13.05 | 12.80 | 12.81 | 42,868 | |
05/21/2024 | 12.78 | 12.94 | 12.61 | 12.91 | 63,667 |
| 12.99 | 13.10 | 12.52 | 12.52 | 44,436 |
| Backtest Mineralys Therapeutics, | | | Mineralys Therapeutics, History | | | Mineralys Therapeutics, Valuation | Previous | Next |
Mineralys Therapeutics, Trading Date Momentum on May 21, 2024
| On May 22 2024 Mineralys Therapeutics, Common was traded for 12.52 at the closing time. The top price for the day was 13.10 and the lowest listed price was 12.52 . The trading volume for the day was 44.4 K. The trading history from May 22, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 3.02% . The trading delta at closing time against the current closing price is 2.87% . |
Mineralys Therapeutics, Fundamentals Correlations and Trends
By evaluating Mineralys Therapeutics,'s financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Mineralys financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Mineralys Therapeutics, Stock history
Mineralys Therapeutics, investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Mineralys is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Mineralys Therapeutics, will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Mineralys Therapeutics, stock prices may prove useful in developing a viable investing in Mineralys Therapeutics,
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 36.2 M | 31 M | |
| Net Loss | -26.8 M | -28.2 M |
Mineralys Therapeutics, Quarterly Net Working Capital |
|
Mineralys Therapeutics, Stock Technical Analysis
Mineralys Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Mineralys Therapeutics, Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Mineralys Therapeutics, Common cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Mineralys Therapeutics, December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Mineralys Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Mineralys Therapeutics, shares will generate the highest return on investment. By undertsting and applying Mineralys Therapeutics, stock market strength indicators, traders can identify Mineralys Therapeutics, Common entry and exit signals to maximize returns
Mineralys Therapeutics, Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Mineralys Therapeutics,'s price direction in advance. Along with the technical and fundamental analysis of Mineralys Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Mineralys to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0511 | |||
| Jensen Alpha | (0.001) | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0302 | |||
| Treynor Ratio | 0.1139 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.